Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KYMR Kymera Therapeutics, Inc.

Market Closed 08-07 16:00:00 EDT

107.52

+1.11

+1.04%

盘后107.52

+0.000.00%

19:34 EDT

High108.12	Low104.78	Vol463.57K
Open106.61	D1 Closing106.41	Amplitude3.14%
Mkt Cap8.94B	Tradable Cap6.92B	Total Shares83.15M
T/O49.44M	T/O Rate0.72%	Tradable Shares64.38M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KYMR","market":"US","secType":"STK","nameCN":"Kymera Therapeutics, Inc.","latestPrice":107.52,"timestamp":1786132800000,"preClose":106.41,"halted":0,"volume":463574,"hourTrading":{"tag":"盘后","latestPrice":107.52,"preClose":107.52,"latestTime":"19:34 EDT","volume":4349,"amount":467604.54,"timestamp":1786145648465,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.010431350436989,"floatShares":64380433,"shares":83150618,"eps":-3.212195,"marketStatus":"Market Closed","change":1.11,"latestTime":"08-07 16:00:00 EDT","open":106.61,"high":108.12,"low":104.78,"amount":49439912.1343,"amplitude":0.031388,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.212195,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786348800000},"marketStatusCode":7,"adr":0,"listingDate":1597982400000,"exchange":"NASDAQ","adjPreClose":106.41,"preHourTrading":{"tag":"盘前","latestPrice":106.34,"preClose":106.41,"latestTime":"09:29 EDT","volume":1541,"amount":165298.362245,"timestamp":1786109399999,"change":-0.07,"changeRate":-0.000658,"amplitude":0.093976},"postHourTrading":{"tag":"盘后","latestPrice":107.52,"preClose":107.52,"latestTime":"19:34 EDT","volume":4349,"amount":467604.54,"timestamp":1786145648465,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8055320008912178,"impliedVol":0.4544,"impliedVolPercentile":0.012},"requestUrl":"/m/hq/s/KYMR","defaultTab":"news","newsList":[{"id":"2657657085","title":"Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657085","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657085?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:11","pubTimestamp":1786047072,"startTime":"0","endTime":"0","summary":"Halozyme Q2 revenue jumps 48%, raises 2026 outlookOverviewU.S. biopharma firm's Q2 revenue rose 48% yr/yr, beating analyst expectationsAdjusted EPS for Q2 beat analyst expectationsCompany raised 2026 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","HELX","LGND","FFOX","PBE","IE0009354923.USD","BK4007","IHE","KYMR","BK4139","LU0053671581.USD","LU0566484027.USD","LU1559883803.SGD","RPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657687417","title":"Analyst Reiterates Buy on Kymera, Citing Favorable BROADEN2 Design and Compelling KT-621 Risk-Reward in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2657687417","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657687417?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:37","pubTimestamp":1786012636,"startTime":"0","endTime":"0","summary":"Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Kymera Therapeutics, with a price target of $134.00. Andrew Fein has given his Bu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-kymera-citing-favorable-broaden2-design-and-compelling-kt-621-risk-reward-in-atopic-dermatitis-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-kymera-citing-favorable-broaden2-design-and-compelling-kt-621-risk-reward-in-atopic-dermatitis-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SG9999004220.SGD","KT","LU0541501648.USD","BK4115","LU0541502299.USD","BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657823606","title":"Kymera Therapeutics, Inc. : Citigroup Raises Target Price to $135 from $120","url":"https://stock-news.laohu8.com/highlight/detail?id=2657823606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657823606?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:13","pubTimestamp":1786011238,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN4430ZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657681415","title":"Kymera Therapeutics price target raised to $139 from $133 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2657681415","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657681415?lang=en_us&edition=fundamental","pubTime":"2026-08-06 17:35","pubTimestamp":1786008929,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Kymera Therapeutics (KYMR) to $139 from $133 and keeps an Overweight rating on the shares. Published fir...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-price-target-raised-to-139-from-133-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-price-target-raised-to-139-from-133-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657575666","title":"Tenaya Therapeutics Q2 Net Loss Widens on Impairment Charge","url":"https://stock-news.laohu8.com/highlight/detail?id=2657575666","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657575666?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:46","pubTimestamp":1785962781,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Q2 net loss widens on impairment chargeOverviewUS heart disease therapy developer's Q2 net loss widened, driven by impairment chargeCompany received $10 mln upfront payment from Al","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421DL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4588","TNYA","KYMR","TRDA","PBE","LU0320765992.SGD","GNMX","BK4585","IMRX","LU0889565916.HKD","BK4548","BK4139","LU0882574055.USD","BK4563","LU0114720955.EUR","ALNY","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657578623","title":"Vir Biotechnology Q2 Revenue Up, Beats Estimates on Astellas Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2657578623","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657578623?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:20","pubTimestamp":1785961240,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Q2 revenue up, beats estimates on Astellas paymentOverviewU.S. biopharma's Q2 revenue rose sharply, beating analyst expectationsQ2 net income was $80.1 mln, reversing a net loss last","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421BR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","SG9999015945.SGD","LU1061106388.HKD","IE00BJT1NW94.SGD","LU0114720955.EUR","IBB","LU1066051498.USD","LU1585245621.USD","LU2087621335.USD","LU0058720904.USD","LU0289739699.SGD","LU0965509101.SGD","TMED","IE00BJJMRZ35.SGD","IE00BSNM7G36.USD","GILD","LU0889565916.HKD","LU1057294990.SGD","BK4532","TBXU","IE00B4R5TH58.HKD","BK4535","LU1571399168.USD","KYMR","LU0868494617.USD","VIR","LU1983299246.USD","AMGN","SG9999015978.USD","IE00B19Z3B42.SGD","BBH","PBE","BK4550","LU2324357040.USD","BK4599","LU1934455863.HKD","LU0823416689.USD","LU1674673691.USD","MEDI","BK4568","LU1430594728.SGD","BMED","IBBQ","BIB","IE00B3T34201.USD","LU0861579265.USD","IE0002270589.USD","LU0234570918.USD","LU0882574055.USD","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657520170","title":"Biopharma Firm Xencor's Q2 Revenue Beats on Royalty Revenue, Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2657520170","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657520170?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:13","pubTimestamp":1785960830,"startTime":"0","endTime":"0","summary":"Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone paymentsOverviewUS biopharma firm's Q2 revenue rose, beating analyst expectationsCompany posted narrower net loss of $21.7 mln, o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421AV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBE","KYMR","BK4539","ZBIO","XNCR","BK4563","IHE","IMRX","BK4007","BK4139","RPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657752095","title":"Editas Medicine Q2 Net Loss Narrows and Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657752095","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657752095?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:11","pubTimestamp":1785960676,"startTime":"0","endTime":"0","summary":"Editas Medicine Q2 net loss narrows and beats estimatesOverviewUS gene editing firm's Q2 net loss narrowed and beat analyst expectationsCollaboration and other R&D revenue more than tripled yr/yr to $","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421AG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","LU1861559042.SGD","BK4611","KYMR","ARKG","BK4588","LU1861558580.USD","EDIT","CRSP","BK4139","BK4585","TRDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657540539","title":"Kymera Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657540539","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657540539?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:31","pubTimestamp":1785936701,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings SummaryKymera Therapeutics, Inc.KYMR.OQreported a quarterly adjusted loss of 62 cents per share for the quarter ended","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N442233:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657544327","title":"Kymera Therapeutics Posts Corporate Deck Outlining Push to Develop Oral Targeted Protein Degraders for Immunology","url":"https://stock-news.laohu8.com/highlight/detail?id=2657544327","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657544327?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:09","pubTimestamp":1785931773,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics posts corporate deck outlining push to develop oral targeted protein degraders for immunologyKymera outlined a strategy to commercialize oral targeted protein degraders in immunolo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL5CKm1M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657541247","title":"Kymera Q2 2026 Earnings: Milestone Revenue Narrows Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657541247","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657541247?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:44","pubTimestamp":1785930281,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics’ Q2 2026 collaboration revenue rose to $65.0 million from $11.5 million, driven by $45 million from Gilead and $20 million from Sanofi. Net loss narrowed to $61.2 million, or $0.62 per share, even as R&D spending increased to $119.5 million. The company ended June with $1.5 billion in cash and investments, supporting a stated runway into 2029. Operationally, Kymera completed enrollment in the KT-621 Phase 2b atopic dermatitis trial nearly six months early and moved the expected topline readout forward to year-end 2026.","market":"nz","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock4.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock4.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262077936-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657215546","title":"Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657215546","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657215546?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:15","pubTimestamp":1785928500,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimatesOverviewUS biopharma firm's Q2 collaboration revenue rose sharply, beating analyst expectationsNet loss for Q2 narrowed c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","SG9999015986.USD","LU2087621335.USD","LU0965509101.SGD","LU0882574055.USD","LU1934455863.HKD","BK4139","LU1066053197.SGD","TBXU","LU0114720955.EUR","BMED","IE00BSNM7G36.USD","BK4568","TMED","IE00B19Z3B42.SGD","SG9999015978.USD","IBB","LU1585245621.USD","LU0965508806.USD","BK4588","LU0823416689.USD","LU0965509010.AUD","KYMR","BK4578","LU1674673428.USD","LU1934455277.USD","BBH","LU1839511570.USD","STOK","LU0965509283.SGD","TYRA","LU0861579265.USD","SG9999015945.SGD","MEDI","LU1934455194.USD","IBBQ","LU0320765992.SGD","IE00BKVL7J92.USD","LU1778281490.HKD","GILD","BK4550","BK4566","BIB","LU1037948541.HKD","LU1061106388.HKD","LU1066051498.USD","BK4585","LU0109394709.USD","IE00B3T34201.USD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657546405","title":"Earnings Flash (KYMR) Kymera Therapeutics Posts Q2 Loss $0.62 a Share, vs. FactSet Est of $0.71 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657546405","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657546405?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:13","pubTimestamp":1785928402,"startTime":"0","endTime":"0","summary":"Earnings Flash (KYMR) Kymera Therapeutics Posts Q2 Loss $0.62 a Share, vs. FactSet Est of $0.71 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657546364","title":"Kymera Therapeutics Q2 EPS $(0.62) Beats $(0.72) Estimate, Sales $65.000M Beat $31.165M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657546364","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657546364?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:04","pubTimestamp":1785927872,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.72) by 13.89 percent. This is a 34.74 percent increase over losses of $(0.95) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60942947/kymera-therapeutics-q2-eps-0-62-beats-0-72-estimate-sales-65-000m-beat-31-165m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657545250","title":"Kymera Therapeutics Q2 EPS USD -0.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2657545250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657545250?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:00","pubTimestamp":1785927605,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLX0BD5WB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657545410","title":"Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657545410","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657545410?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:00","pubTimestamp":1785927605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUA5GKHVS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656111693","title":"Kymera Therapeutics (KYMR) Could Be 23% Undervalued On Its New CMO Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2656111693","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656111693?lang=en_us&edition=fundamental","pubTime":"2026-08-02 06:33","pubTimestamp":1785623615,"startTime":"0","endTime":"0","summary":"Why Kymera Therapeutics Stock Is Back In Focus After A C-suite Change\nKymera Therapeutics (KYMR) is in focus after appointing Terence Rooney, MD, as Chief Medical Officer, a change that puts fresh attention on how the company plans its future clinical development work.\nSee our latest analysis for Kymera Therapeutics.\nKymera Therapeutics shares trade at US$103.40 after short term share price weakness, with the stock down 3.37% over one day and 9.46% over 30 days, although a 28.11% 90 day share...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-could-be-23-undervalued-on-its-new","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kymr/kymera-therapeutics/news/kymera-therapeutics-kymr-could-be-23-undervalued-on-its-new","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655823858","title":"Kymera Therapeutics Inc : Deutsche Bank Initiates Coverage with Hold Rating; Target Price $120","url":"https://stock-news.laohu8.com/highlight/detail?id=2655823858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655823858?lang=en_us&edition=fundamental","pubTime":"2026-07-30 14:28","pubTimestamp":1785392919,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nFWN43W0Z5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655982887","title":"Kymera Therapeutics Schedules Quarterly Financial Results Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2655982887","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655982887?lang=en_us&edition=fundamental","pubTime":"2026-07-29 04:01","pubTimestamp":1785268912,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics schedules quarterly financial results webcastKymera Therapeutics will report second-quarter 2026 financial results on Aug. 5, 2026.A video conference call, webcast scheduled for Au","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDLDDrYm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4585","SG9999014005.SGD","BCDF","SG9999014039.USD","BK4588","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU0314104364.USD","BK4112","KYMR","SG9999014021.USD","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654144005","title":"Kymera Therapeutics price target raised to $135 from $125 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2654144005","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654144005?lang=en_us&edition=fundamental","pubTime":"2026-07-28 18:40","pubTimestamp":1785235235,"startTime":"0","endTime":"0","summary":"Guggenheim raised the firm’s price target on Kymera Therapeutics (KYMR) to $135 from $125 and keeps a Buy rating on the shares. Kymera could gain s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-price-target-raised-to-135-from-125-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-price-target-raised-to-135-from-125-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kymeratx.com","stockEarnings":[{"period":"1week","weight":0.0398},{"period":"1month","weight":-0.0582},{"period":"3month","weight":0.2491},{"period":"6month","weight":0.3509},{"period":"1year","weight":1.6321},{"period":"ytd","weight":0.3818}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.060685},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.014692},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.075866},{"month":4,"riseRate":0.5,"avgChangeRate":0.006528},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.121889},{"month":6,"riseRate":0.666667,"avgChangeRate":0.163264},{"month":7,"riseRate":0.666667,"avgChangeRate":0.127227},{"month":8,"riseRate":0.666667,"avgChangeRate":0.036027},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.031798},{"month":10,"riseRate":0.666667,"avgChangeRate":0.069597},{"month":11,"riseRate":0.666667,"avgChangeRate":0.180891},{"month":12,"riseRate":0.666667,"avgChangeRate":0.094258}],"exchange":"NASDAQ","name":"Kymera Therapeutics, Inc.","nameEN":"Kymera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kymera Therapeutics, Inc.(KYMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kymera Therapeutics, Inc.,KYMR,Kymera Therapeutics, Inc.股票,Kymera Therapeutics, Inc.股票老虎,Kymera Therapeutics, Inc.股票老虎国际,Kymera Therapeutics, Inc.行情,Kymera Therapeutics, Inc.股票行情,Kymera Therapeutics, Inc.股价,Kymera Therapeutics, Inc.股市,Kymera Therapeutics, Inc.股票价格,Kymera Therapeutics, Inc.股票交易,Kymera Therapeutics, Inc.股票购买,Kymera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kymera Therapeutics, Inc.(KYMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}